Oxaliplatin

Generic Name
Oxaliplatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H14N2O4Pt
CAS Number
61825-94-3
Unique Ingredient Identifier
04ZR38536J
Background

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication

Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions
Advanced Colorectal Cancer, Stage III Colon Cancer
Associated Therapies
-
Clinical Trials
Related News

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

First Posted Date
2023-01-18
Last Posted Date
2024-02-01
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
56
Registration Number
NCT05688215
Locations
🇺🇸

Yonemoto,Lisa, Los Angeles, California, United States

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

First Posted Date
2023-01-18
Last Posted Date
2023-04-19
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Target Recruit Count
140
Registration Number
NCT05687357
Locations
🇨🇳

Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China

🇨🇳

Wuhan Tongji Hospital, Wuhan, Hubei, China

🇨🇳

Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

First Posted Date
2023-01-10
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
382
Registration Number
NCT05677490
Locations
🇺🇸

CARTI Cancer Center, Little Rock, Arkansas, United States

🇺🇸

Sutter Auburn Faith Hospital, Auburn, California, United States

🇺🇸

Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States

and more 729 locations

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Phase 2
Recruiting
Conditions
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Esophageal Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Esophageal Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Propranolol Hydrochloride
Other: Questionnaire Administration
First Posted Date
2022-12-15
Last Posted Date
2024-06-14
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
40
Registration Number
NCT05651594
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

First Posted Date
2022-12-07
Last Posted Date
2022-12-07
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
30
Registration Number
NCT05640726

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

First Posted Date
2022-11-28
Last Posted Date
2024-10-01
Lead Sponsor
Fudan University
Target Recruit Count
93
Registration Number
NCT05628038
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

First Posted Date
2022-11-25
Last Posted Date
2024-08-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
86
Registration Number
NCT05627635
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

First Posted Date
2022-11-09
Last Posted Date
2024-04-12
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
10
Registration Number
NCT05611034
Locations
🇨🇦

University Health Network, Toronto General Hospital, Toronto, Ontario, Canada

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

First Posted Date
2022-11-09
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
312
Registration Number
NCT05610163
Locations
🇺🇸

Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States

🇺🇸

Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States

🇺🇸

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 632 locations

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

First Posted Date
2022-11-08
Last Posted Date
2022-11-08
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
45
Registration Number
NCT05608785
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy